Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck

Journal of Chemotherapy

Volumn 9, Issue 1, 1997, Pages 72-76

  Adamo, V ^b   Maisano, R ^a   Pergolizzi, S ^a   Altavilla, G ^b   Caristi, N ^b   Chiofalo, G ^a   Scimone, A ^a   Settineri, N ^a  

^a National Institute for Cancer Research of Genoa   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

bleomycin; carboplatin; epirubicin; head and neck; metastatic; squamous cell carcinoma

Indexed keywords

BLEOMYCIN; CARBOPLATIN; EPIRUBICIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

EID: 0030887359     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1997.9.1.72     Document Type: Article

References (28)

1. Dimery W, Hong WK. Overview of combined modality therapies for head and neck cancer. JNCI 1995; 85, 2: 95-111.
2. Pinto HA, Jacobs C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin North Am 1991; 5: 667-686.
3. Mitchell MS, Wawro NV, DeConti RC et al. Effectiveness of high-dose infusion of methotrexate followed by leucovorin in carcinomas of the head and neck. Cancer Res, 1968; 28: 108-109.
4. Veronesi A, Zagonel V, Rinelli U et al. High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J Clin Oncol 1985; 3:1105-1108.
5. Urba SG, Forastiere AA. Systemic therapy of head and neck cancer: most effective agents of real promise. Oncology 1989; 3: 79-98.
6. Pinto HA, Jacobs C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin North Am 1991; 5: 667-686.
7. Vogl SE. Chemotherapy of recurrent and metastatic head and neck cancer. In: Vogl SE, ed, Head and neck cancer. New York: Churchill Livingstone 1983: 65-77.
8. Pfister PG, Bajorin D, Motzer R et al. Cisplatin/5-fluorouracil/leucovorin (PFL): greater toxicity but no response in squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 1994; 120: 89-95.
9. Al-Sarrat M. Management strategies in head and neck cancer: the role of carboplatin. In: Bunns PA Jr, Canetta R, Ozols RF, Rozencqeig M, eds. Carboplatin (JM-8): current perspectives and future directions. Philadelphia: WB Saunders 1990.
10. Magee MJ, Howard J, Bosl GJ, et al. Phase II trial of 4-epidoxorubicin in advanced carcinoma of head and neck origin. Cancer Treat Rep 1985; 69: 125-129.
11. Karpovsky B, Karp D, Vaughan C,. A phase II randomized trial of weekly versus every 3 weeks pidoxorubicin in advanced squamous cell cancer of head and neck. Proc Am Soc Clin Oncol 1987; 6: 514.
12. Cersosino RJ, Hong WK. Epirubicin: a review of pharmacology, clinical activity and adverse effects of an Adriamycin analogue. J Clin Oncol 1986; 4:425-439.
13. Paccagnella A, Pappagallo GL, Segati R, Zorat P, et al. Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomized study. Eur J Cancer, 1983; 29 A, 5: 704-708.
14. Guaraldi M, Martoni A, Rossi AP, et al. Treatment of advanced head and neck tumors with PEV-B regimen: a pilot study. Chemioterapia 1988; 7(5): 341-4.
15. Giglio R, Cabalar E, Mickiewicz E, et al. Phase II study of high-dose epirubidn as single agent (HDESA) followed by radiotherapy (RT) in patients with locally advanced head and neck tumor. Proc Ann Meet Am Soc Clin Oncol 1992; 11: A 792.
16. Junor E, Canney P, Yosef H. Carboplatin and 5-fluorouracil in advanced and recurrent squamous carcinoma of head and neck. Clin Oncol (Roy Coll Radiol) 1993; 5 (1): 43-45.
17. WHO Handbook for reporting results of cancer treatment. WHO offset publication No 48, Geneva: WHO, 1979.
18. Miller AB, Hoogstratten B, Statquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
19. Kaplan G, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
20. Forastiere AA. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol 1994; 21, 5, Suppl 12: 20 -27.
21. Adelstein DJ. The community approch to salvage therapy for advanced head and neck cancer. Semin Oncol 1994; 21, 4, Suppl 7: 52-57.
22. Skoog LA, Vokes EE. Chemotherapy, biologics, and chemoprevention as systemic therapies of head and neck cancer. Curr Opin Oncol 1994; 6: 277-284.
23. Cappelaere P, Vignond J, Fargeot P, et al. Palliative chemotherapy of epidermoid carcinoma of the upper respiratory and digestive tracts with combination of carboplatin and 5-fluorouracil. Bull Cancer 1990; 77: 1009-1105.
24. Eisenberger M, Krasnow S, Ellenberg S, et al. A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer. J Clin Oncol 1989; 7: 1341-1345.
25. Maipang T, Watanaarepornchai S, Panjapiyakul C, et al. Cisplatinum-epirubicin chemotherapv for advanced unresectable squamous cell carcinoma of the head and neck. Head Neck 1993; 15(2): 109-114.
26. Bachouchi M, Cvitkovic E, Nasser A, et al. High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. JNCI 1990; 82, 7: 616-620.
27. Adamo V, Maisano R, Pergolizzi S, Altavilla G, Caristi N, Chiofalo G, Scimone A. Bleomycin, epidoxorubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of head and neck (SCCHN): A phase II study. Ann Oncol 1994; 5 (suppl.8): 1994, abst. P598, 119.
28. Altun M, Fandi A, Dupuis O, Cvitkovic E, Krajina Z, Eschwege F. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995; 32, 3:859-877.